A pharmaceutical project manager is leading a predictive drug development project with a fixed deadline driven by patent expiration timelines. A key supplier who provides specialized testing equipment has just filed for bankruptcy protection. This supplier represents 30% of the project's critical path activities. Two alternative suppliers exist: Supplier A can deliver in six weeks at 140% of the original cost but with proven reliability, while Supplier B offers delivery in three weeks at 95% of original cost but has limited track record in pharmaceutical applications. The project's contingency reserve is 12% of total budget. The compliance officer warns that using an unproven supplier could jeopardize FDA validation. What is the MOST appropriate action?

Question

Accepted Answer

The correct answer is A. In a highly regulated industry like pharmaceuticals with FDA validation requirements, compliance cannot be compromised regardless of cost or schedule pressures. Supplier A's proven reliability and track record in pharmaceutical applications make it the only viable choice despite the cost premium. Management reserve (not contingency reserve) is appropriate here because supplier bankruptcy is an unforeseeable risk outside the identified risk register. Option B (main distractor) is tempting for cost reasons, but jeopardizing FDA validation could result in complete project failure, rejection of the drug application, and losses far exceeding the cost savings. In predictive pharmaceutical projects, regulatory compliance always takes precedence over cost optimization. Option C's force majeure claim is likely invalid (supplier bankruptcy is a manageable risk), and Option D wastes resources and doesn't solve the compliance concern.

PMP Practice Question: Business Environment — Predictive, Hard

More Business Environment Questions